This site is intended for healthcare professionals
Prostatic tissue biopsy; Sections show fatty tissue, neural tissue and muscle tissue; Prostate cancer diagnosis
HRR Mutation Testing in mPC

Learning Zone feedback

Last updated: 24th Nov 2025
Published: 18th Jan 2025
Declaration of sponsorship: Pfizer
HRR Mutation Testing in mPC – Overview
1. This program contained content relevant to my clinical practice
2. After visiting this Learning Zone, how likely are you to use your patient’s HRR mutation status to guide their management of mPC?
3. After viewing this resource, how likely are you to change your approach to deciding which patients with prostate cancer to test for HRR mutations?
4. Based on this Learning Zone, how likely are you to change when you test patients with prostate cancer for HRR mutations?
5. After viewing this resource, how likely are you to change your approach to biopsy methods for HRR mutation testing?
6. Would you be willing to give us further input on your experience of this Learning Zone in a follow-up 15–20-minute interview? If yes, we will contact you via the email we have linked to your Medthority account.
7. The content was fair and balanced, and free from commercial bias

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.